[Federal Register Volume 62, Number 155 (Tuesday, August 12, 1997)]
[Notices]
[Page 43185]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-21247]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration
By Notice dated March 12, 1997, and published in the Federal
Register on March 19, 1997, (62 FR 13169), Glaxo Wellcome Inc., Attn:
Jeffrey A. Weiss, 1011 North Arendell Avenue, P.O. Box 1217, Zebulon,
North Carolina 27597-2309, made application to the Drug Enforcement
Administration to be registered as an importer of remifentanil (9739),
a basic class of controlled substance listed in Schedule II.
No comments or objections have been received. DEA has considered
the factors in Title 21, United States Code, Section 823(a) and
determined that the registration of Glaxo Wellcome Inc. to import
remifentanil is consistent with the public interest and with United
States obligations under international treaties, conventions, or
protocols in effect on May 1, 1971, at this time. Therefore, pursuant
to Section 1008(a) of the Controlled Substances Import and Export Act
and in accordance with Title 21, Code of Federal Regulations, Section
1301.34, the above firm is granted registration as an importer of the
basic class of controlled substance listed above.
Dated: July 28, 1997.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 97-21247 Filed 8-11-97; 8:45 am]
BILLING CODE 4410-09-M
